MX2019001718A - Fracciones de plasma sanguineo como tratamiento para trastornos cognitivos asociados con el envejecimiento. - Google Patents

Fracciones de plasma sanguineo como tratamiento para trastornos cognitivos asociados con el envejecimiento.

Info

Publication number
MX2019001718A
MX2019001718A MX2019001718A MX2019001718A MX2019001718A MX 2019001718 A MX2019001718 A MX 2019001718A MX 2019001718 A MX2019001718 A MX 2019001718A MX 2019001718 A MX2019001718 A MX 2019001718A MX 2019001718 A MX2019001718 A MX 2019001718A
Authority
MX
Mexico
Prior art keywords
aging
blood plasma
treatment
cognitive disorders
plasma fractions
Prior art date
Application number
MX2019001718A
Other languages
English (en)
Inventor
Bell David
Dang Vu
Gallager Ian
P Braithwaite Steven
Sakura Minami S
Mccracken Joe
Nikolich Karoly
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of MX2019001718A publication Critical patent/MX2019001718A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen métodos y composiciones para tratar y/o prevenir condiciones relacionadas con el envejecimiento; las composiciones usadas en los métodos incluyen fracciones derivadas de plasma sanguíneo con eficacia en el tratamiento y/o prevención de condiciones relacionadas con el envejecimiento como trastornos neurocognitivos.
MX2019001718A 2016-08-18 2017-04-27 Fracciones de plasma sanguineo como tratamiento para trastornos cognitivos asociados con el envejecimiento. MX2019001718A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376529P 2016-08-18 2016-08-18
US201662412258P 2016-10-24 2016-10-24
PCT/US2017/029953 WO2018034712A1 (en) 2016-08-18 2017-04-27 Blood plasma fractions as a treatment for aging-associated cognitive disorders

Publications (1)

Publication Number Publication Date
MX2019001718A true MX2019001718A (es) 2019-09-13

Family

ID=61196950

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001718A MX2019001718A (es) 2016-08-18 2017-04-27 Fracciones de plasma sanguineo como tratamiento para trastornos cognitivos asociados con el envejecimiento.
MX2024008963A MX2024008963A (es) 2016-08-18 2019-02-11 Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024008963A MX2024008963A (es) 2016-08-18 2019-02-11 Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.

Country Status (28)

Country Link
US (2) US20190321449A1 (es)
EP (2) EP3995140A1 (es)
JP (3) JP7316931B2 (es)
KR (3) KR20190032614A (es)
CN (2) CN115957309A (es)
AU (4) AU2017312722B2 (es)
BR (1) BR112019003172A2 (es)
CA (1) CA3033051A1 (es)
CL (1) CL2019000304A1 (es)
CY (1) CY1124695T1 (es)
DK (1) DK3484502T3 (es)
ES (1) ES2899147T3 (es)
HR (1) HRP20211628T1 (es)
HU (1) HUE056294T2 (es)
IL (2) IL304946A (es)
LT (1) LT3484502T (es)
MA (1) MA45692B1 (es)
MD (1) MD3484502T2 (es)
MX (2) MX2019001718A (es)
NZ (1) NZ750885A (es)
PL (1) PL3484502T3 (es)
PT (1) PT3484502T (es)
RS (1) RS62558B1 (es)
SG (1) SG11201901273TA (es)
SI (1) SI3484502T1 (es)
UA (1) UA126232C2 (es)
WO (1) WO2018034712A1 (es)
ZA (1) ZA202004834B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3615057T3 (da) * 2017-04-26 2024-01-02 Alkahest Inc Doseringsskema til behandling af kognitive svækkelser med blodplasmaprodukter
SG11202010115RA (en) 2018-05-15 2020-11-27 Alkahest Inc Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
CN110724176B (zh) * 2018-07-16 2021-10-26 北京豪思生物科技有限公司 一种治疗阿尔茨海默症的血浆蛋白分离物及其制备方法和应用
CN110787187B (zh) * 2018-07-16 2022-05-13 北京豪思生物科技股份有限公司 一种增强记忆力和提高认知功能的血浆混合物及其制备方法和应用
EP4374921A3 (en) * 2018-07-20 2024-06-19 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
JP7504090B2 (ja) 2018-10-26 2024-06-21 アルカヘスト，インコーポレイテッド 疼痛、創傷治癒及び術後回復の改善のための血漿及び血漿画分の使用
CN110448686B (zh) * 2019-09-19 2022-11-04 北京豪思生物科技股份有限公司 铜蓝蛋白联合运铁蛋白的应用
WO2021062007A1 (en) * 2019-09-25 2021-04-01 Cytegen Corp. Treatment of mitochondrial deficits and age-related diseases using blood products
US11439687B2 (en) 2019-11-04 2022-09-13 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
CA3156906A1 (en) 2019-11-20 2021-05-27 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
EP4426284A1 (en) 2021-11-01 2024-09-11 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases
WO2024102244A1 (en) * 2022-11-11 2024-05-16 Alkahest, Inc. Blood plasma fractions for improvement of myelination

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869431A (en) 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3612137A1 (de) * 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5110907A (en) 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US20050143310A1 (en) * 2001-05-11 2005-06-30 Masaki Hirashima Novel remedies for neurodegenerative disease
AU2003303198A1 (en) * 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
US20040146565A1 (en) * 2003-01-28 2004-07-29 Lauridsen Group Incorporated First lipoprotein fraction and therapeutic compositions of same
US20130121979A1 (en) * 2003-12-29 2013-05-16 Allan Mishra Method of treating cancer using platelet compositions
ES2257225B1 (es) 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
EP2271382B1 (en) 2008-04-15 2013-03-13 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
WO2009155069A1 (en) * 2008-05-28 2009-12-23 Allan Mishra Compositions and methods for treating psychiatric and neurodegenerative disorders
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
PT2994160T (pt) * 2013-05-06 2019-08-07 Baxalta Inc Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
AU2014364182B2 (en) * 2013-12-09 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
ES2524516B1 (es) 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EA039316B1 (ru) * 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
DK3615057T3 (da) * 2017-04-26 2024-01-02 Alkahest Inc Doseringsskema til behandling af kognitive svækkelser med blodplasmaprodukter

Also Published As

Publication number Publication date
ES2899147T3 (es) 2022-03-10
CY1124695T1 (el) 2022-07-22
EP3995140A1 (en) 2022-05-11
RS62558B1 (sr) 2021-12-31
WO2018034712A1 (en) 2018-02-22
MA45692B1 (fr) 2021-10-29
AU2017312722B2 (en) 2020-01-02
CA3033051A1 (en) 2018-02-22
IL264660B2 (en) 2024-03-01
HUE056294T2 (hu) 2022-02-28
NZ750885A (en) 2021-07-30
MX2024008963A (es) 2024-07-30
US20220152161A1 (en) 2022-05-19
LT3484502T (lt) 2021-12-10
JP7316931B2 (ja) 2023-07-28
CL2019000304A1 (es) 2019-05-31
JP2023156459A (ja) 2023-10-24
BR112019003172A2 (pt) 2019-05-28
ZA202004834B (en) 2022-07-27
KR20190032614A (ko) 2019-03-27
AU2020200181A1 (en) 2020-01-30
PT3484502T (pt) 2021-11-18
AU2024219765A1 (en) 2024-10-10
HRP20211628T1 (hr) 2022-02-04
PL3484502T3 (pl) 2022-01-31
KR20220107322A (ko) 2022-08-02
AU2021240142B2 (en) 2024-06-20
AU2020200181B2 (en) 2021-07-22
EP3484502B1 (en) 2021-08-25
JP7447069B2 (ja) 2024-03-11
IL304946A (en) 2023-10-01
DK3484502T3 (da) 2021-10-25
MA45692A (fr) 2019-05-22
MD3484502T2 (ro) 2022-01-31
SI3484502T1 (sl) 2022-01-31
AU2017312722A1 (en) 2019-03-14
CN109963582B (zh) 2022-12-27
IL264660A (es) 2019-04-30
EP3484502A1 (en) 2019-05-22
EP3484502A4 (en) 2020-03-04
SG11201901273TA (en) 2019-03-28
JP2019528269A (ja) 2019-10-10
JP2022037124A (ja) 2022-03-08
KR20240036720A (ko) 2024-03-20
CN109963582A (zh) 2019-07-02
IL264660B1 (en) 2023-11-01
CN115957309A (zh) 2023-04-14
US20190321449A1 (en) 2019-10-24
UA126232C2 (uk) 2022-09-07
AU2021240142A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2024008963A (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
ZA202301009B (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
IL264028A (en) Crispr/cas9-based preparations and methods for the treatment of retinal degeneration
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
ZA202101362B (en) Compositions and methods for treating the eye
PH12017501864A1 (en) Compositions and methods for treating autism
IL265635A (en) Combined treatments including imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
MX2021000707A (es) Regimen de dosificacion para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
ZA202101342B (en) Compositions and methods for treating the eye
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
ZA202101361B (en) Compositions and methods for treating the eye
ZA202101360B (en) Compositions and methods for treating the eye
ZA202007183B (en) Compositions and methods for treating the eye
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy
HK1257911A1 (zh) 7，8二羥基黃酮在治療或預防老齡化相關的認知能力下降中的用途
EP3421025A4 (en) METHOD FOR TREATMENT AND PREVENTION OF PERIPHERAL BLOOD CIRCULATION DISORDERS AND INVERSION TABLE FOR IMPLEMENTATION THEREOF
IL268844A (en) Peptides and methods of treating dystrophy-related diseases by them